Last updated: July 28, 2026
Litigation summary: King Pharmaceuticals Inc. v. Intelliject Inc., 1:11-cv-00065
King Pharmaceuticals Inc. v. Intelliject Inc., 1:11-cv-00065, is a US patent infringement dispute filed in 2011. The record required to produce a complete, case-grade litigation summary and enforceability analysis (asserted patents, claims, venue court, pleadings timeline, Markman outcomes, claim construction, dispositive motions, settlement terms, and final judgment) is not present in the provided input, so a complete and accurate litigation analysis cannot be produced.
What patents are asserted in King Pharmaceuticals Inc. v. Intelliject Inc. (1:11-cv-00065)?
A litigation summary requires the asserted patent numbers and the asserted claims. Those details are not included in the input.
Which patent holders and assignees are named?
This requires the complaint’s patent ownership and assignment chain as pleaded. Not provided.
Which technology is covered (drug, formulation, method of use, device)?
This requires the infringement theory in the complaint and claim chart content. Not provided.
What claims does King Pharmaceuticals allege Intelliject infringes?
A claim-by-claim infringement analysis requires the complaint’s asserted claim list and the accused product(s) or process(es). Not provided.
Are there Paragraph IV or generic entry issues?
Paragraph IV status is specific to Hatch-Waxman and requires FDA Orange Book listing linkage and the complaint’s regulatory posture. Not provided.
Is the case about formulation, dosing device, or delivery technology?
Technology mapping needs the complaint’s technical allegations. Not provided.
Procedural timeline: when was each key event filed or decided?
A reliable litigation timeline requires docket dates for summons/service, complaint filing, answer, amended pleadings, claim construction (Markman), summary judgment, trial dates, and any appeals. Not provided.
Complaint, answer, and amendments: what changed?
Requires filed pleading identifiers and dates. Not provided.
Markman and claim construction outcomes?
Requires the claim construction order(s). Not provided.
Motion practice: what did the court grant or deny?
A motion practice analysis requires the exact motion types (12(b)(6), 101, 102/103, indefiniteness, venue, personal jurisdiction, preliminary injunction, summary judgment), the granted/denied outcomes, and key holdings. Not provided.
Does the case involve §101 patent-eligibility challenges?
Requires the presence and outcome of §101 motions. Not provided.
Are there invalidity theories tied to prior art?
Requires prior art references and the court’s reasoning. Not provided.
Settlement, license, or consent judgments: what is the resolution?
A resolution analysis requires confirmation of the settlement status and any consent decree, dismissal with prejudice, standstill, or license agreement terms. Not provided.
Was there a final judgment or stipulated dismissal?
Requires docket dispositions and dates. Not provided.
Were there ongoing injunctions or royalty obligations?
Requires any court order or settlement document. Not provided.
How strong was King’s infringement case and how do the defenses impact enforceability?
A strength-of-case assessment requires:
- asserted claim scope
- construed claim terms
- accused product mapping
- infringement and invalidity outcomes
- any appellate history
None of these are included in the input.
Which court handled the case, and what is the venue’s procedural posture?
A litigation summary requires the court name and division (district, judge), plus any related cases or consolidated proceedings. Not provided.
Are there related cases with the same parties or patents?
Requires docket cross-references. Not provided.
Comparable litigation: how does this case align with similar King Pharmaceuticals IP disputes?
A comparative analysis requires identification of:
- overlapping patents
- similar product categories
- common defenses (indefiniteness, noninfringement, obviousness)
Not provided.
Key takeaways for business and licensing teams
- The case identifier (1:11-cv-00065) alone is not sufficient to generate a litigation summary that is accurate at the patent-assertion and enforceability level.
- A case-grade analysis depends on docket-specific facts (asserted patents and claims, construed terms, dispositive holdings, and resolution terms), none of which are included in the input.
FAQs
1) Who were the judges and parties in King Pharmaceuticals Inc. v. Intelliject Inc., 1:11-cv-00065?
Not provided.
2) What patents were asserted and which claims were targeted?
Not provided.
3) Did the court conduct a Markman hearing or issue claim construction orders?
Not provided.
4) Did the case end in settlement, dismissal, or judgment after trial?
Not provided.
5) Are any appeals or post-judgment enforcement actions documented?
Not provided.
